Latest / Pharmacy Podcast Network / Exploring Non-Stimulant ADHD Treatment Strategies with Dr Richard Price | Managing ADHD- A Lifelong Challenge
Transcript
- 0:07Speaker 1: Thanks for listening to the Pharmacy Podcast Network.
- 0:24Speaker 2: Currently, there are over thirty stimulant products on the market
- 0:27Speaker 2: for ADHD. However, when it comes to non stimulant options,
- 0:31Speaker 2: the choice of therapy is very limited for people with
- 0:34Speaker 2: ADHD or parents caring for children with ADHD who want
- 0:38Speaker 2: to avoid stimulants due to concerns of diversion, misuse, or
- 0:41Speaker 2: side effects. This show will explain what other ADHD options
- 0:45Speaker 2: are available and discuss data supporting optimizing its use. The
- 0:49Speaker 2: views and opinions expressed on this podcast are solely those
- 0:52Speaker 2: of doctor Price. These views and opinions do not necessarily
- 0:55Speaker 2: represent those of our sponsor. Doctor Price was not financially
- 0:59Speaker 2: compensated by Supers and this pharmaceutical for his participation in
- 1:02Speaker 2: this podcast.
- 1:04Speaker 3: Hey, what a special opportunity to dive into something that
- 1:07Speaker 3: is really pertinent and timely. You know, we're headed into
- 1:12Speaker 3: a new year, and when I think of this new year,
- 1:15Speaker 3: I'm seeing so many roles of the pharmacies. Pharmacists within
- 1:19Speaker 3: pharmacies are changing. We see much more dive into conditions
- 1:24Speaker 3: we're talking about. The network has pediatric focus podcasts where
- 1:29Speaker 3: doctor Jenna Quinn is really diving into specific situations that
- 1:33Speaker 3: they've experienced and they they've taken a diagnosis and they've
- 1:38Speaker 3: run with the treatment, then they've fed back the physician.
- 1:40Speaker 1: So one of the subjects that keeps coming up.
- 1:43Speaker 3: And there was an article out of the Syracuse University
- 1:47Speaker 3: News and this was published back in October of twenty
- 1:50Speaker 3: twenty four. It says what's driving the rise in ADHD
- 1:54Speaker 3: diagnosis among children and adults? And this is a really
- 1:58Speaker 3: interesting article. They go into some of the statistics and saying,
- 2:02Speaker 3: according to a twenty twenty one report the Journal of
- 2:06Speaker 3: Managed Care and Specialty Pharmacy, eight point seven million adults
- 2:11Speaker 3: in the United States have ADHD. Now, as someone who
- 2:15Speaker 3: experienced a lot of what was called back in my day,
- 2:19Speaker 3: I went to Catholic school in grade school and I
- 2:23Speaker 3: was told by my teachers and my parents that I
- 2:28Speaker 3: was hyperactive and they didn't say ADHD in nineteen seventy
- 2:34Speaker 3: what was that eight or seventy nine. But now we
- 2:38Speaker 3: know what's going on. There's a lot more data, there's
- 2:40Speaker 3: a lot more involvement. I want to welcome to this
- 2:42Speaker 3: podcast a special opportunity to learn from doctor Richard Price.
- 2:48Speaker 3: It is so good to have you here. Richard and
- 2:51Speaker 3: I really appreciate you taking the time to talk with us.
- 2:53Speaker 4: Thank you so much for having me.
- 2:55Speaker 3: So give us some background with your research and your
- 2:58Speaker 3: knowledge and the work that you're doing with Supernas, because
- 3:00Speaker 3: we're very proud that they're helping us with this episode
- 3:04Speaker 3: and bringing this information, helping us bring this information to
- 3:07Speaker 3: the table. So talk to us about your background and
- 3:10Speaker 3: what you've dug into with regards to ADHD and especially
- 3:13Speaker 3: in children.
- 3:16Speaker 5: Oh sure, So I'm West Philadelphia born and raised. I
- 3:20Speaker 5: went to college at Columbia and did my residency training
- 3:23Speaker 5: in psychiatry at Yale, and I'm currently a professor of
- 3:26Speaker 5: psychiatry at wild Cornell Medical College in New York. And
- 3:30Speaker 5: I have various practices throughout the state, federally funded and
- 3:34Speaker 5: state funded and supervised position assistants and as practitioners.
- 3:39Speaker 4: And I have an oldiestic approach to.
- 3:41Speaker 5: My practice private practice as well in Muncie, New York,
- 3:44Speaker 5: and I've been doing it for the past that twenty
- 3:47Speaker 5: years or so. And I see children, adolescents, adults, seniors,
- 3:50Speaker 5: couples pretty much for all conditions. So although ADHD is
- 3:54Speaker 5: a large part of what I see, it's not the
- 3:56Speaker 5: only thing that I see, and I think it's important
- 3:59Speaker 5: to look at the whole person in front of you
- 4:02Speaker 5: and not carved them up into various diagnoses and try
- 4:06Speaker 5: to match treatment to their entire profile. I got involved
- 4:10Speaker 5: with supernas because my son he is a medical student
- 4:15Speaker 5: and aspiring a psychiatrist as well, and we're always looking.
- 4:19Speaker 4: For research projects that we could do.
- 4:21Speaker 5: And a few years ago there was a new medication
- 4:25Speaker 5: that came to the market called voloxazine e er Calbri,
- 4:28Speaker 5: and we found that a lot of people were comparing
- 4:31Speaker 5: it to an old medication called atomoxetine straterra, but we
- 4:35Speaker 5: were seeing that it was quite different, and we conducted
- 4:39Speaker 5: a study looking at patients who had taken straterra and
- 4:44Speaker 5: had then switched over to atomoxity, from atomoxtines to calbrey
- 4:49Speaker 5: and we collected the data real world data crossover studies,
- 4:54Speaker 5: so each group was its own control.
- 4:56Speaker 4: And we published that.
- 4:57Speaker 5: In CNS Drugs in Lie of twenty twenty three, not
- 5:02Speaker 5: too long ago, and that paper went around the world
- 5:05Speaker 5: as a landmark study highlighting some of the differences that
- 5:10Speaker 5: calbri offers, the advantages and the soalibility and the efficacy
- 5:16Speaker 5: above adam oxy, which people never really appreciated, and through that,
- 5:22Speaker 5: the makers of Calbre Supernas discovered the paper and they
- 5:27Speaker 5: thought it was very worthwhile.
- 5:30Speaker 4: And they're.
- 5:32Speaker 5: Educating the community about the differences which people hadn't appreciated before.
- 5:36Speaker 5: So the study was entirely funded by US, no industry
- 5:39Speaker 5: involvement there, but we just wanted to share the information
- 5:43Speaker 5: so people could learn about new treatments that could change
- 5:46Speaker 5: the paradigm and change the landscape in ADHD. I'm the
- 5:48Speaker 5: son of a pharmacist, so it's very near and due
- 5:50Speaker 5: to my heart that I'm on a pharmacy podcast. And
- 5:54Speaker 5: my mother was a nurse, so that's my background, and
- 5:57Speaker 5: I grew up in the helping and healing professions. I'm rabbi,
- 6:00Speaker 5: so I take a spiritual approach to things and look
- 6:02Speaker 5: at lifestyle issues and non pharmacologic interventions, which of course
- 6:06Speaker 5: are always the first line in mental health before we
- 6:09Speaker 5: jump to medications.
- 6:10Speaker 4: So that's a little bit about my background.
- 6:13Speaker 1: I love this.
- 6:13Speaker 3: So the reason why I'm so interested in this is
- 6:16Speaker 3: we're seeing a surge in pharmacists becoming experts in a
- 6:21Speaker 3: specific disease and managing the disease treatment, and within that scope,
- 6:26Speaker 3: they're bringing in a holistic approach. They're bringing in spending
- 6:30Speaker 3: time outside, breathing, exercises, exercise, diet, they're bringing in.
- 6:37Speaker 1: Dietitians.
- 6:38Speaker 3: They're really thinking of the whole personalized persons, and it's
- 6:42Speaker 3: different for different people. So you were saying in the
- 6:45Speaker 3: beginning of not carving up people into little blocks and
- 6:50Speaker 3: treating everybody like some kind of uh, you know, big
- 6:54Speaker 3: processing center, a conveyor belt where you're just kind of, hey,
- 6:58Speaker 3: if you have ADHD, let's put you on the drug.
- 7:00Speaker 3: You have ADHD, yep I do okay, let's put you
- 7:03Speaker 3: on this drug. So slowing that down, that analysis of
- 7:08Speaker 3: dialing into the patient specifically, Let's go to kids for
- 7:13Speaker 3: a second. I was a hyperactive child. I remember getting
- 7:16Speaker 3: in trouble because I couldn't concentrate and there was no
- 7:20Speaker 3: such thing as in at least in my neck of
- 7:22Speaker 3: the woods in western southwestern Pennsylvania, Butler, Pennsylvania, the community
- 7:29Speaker 3: wasn't really into medications for kids in those days. We
- 7:33Speaker 3: didn't really have a lot of medicated kids back in
- 7:36Speaker 3: the mid seventies in eighties, and it was more of
- 7:43Speaker 3: they always said, you were just a bad kid, you know,
- 7:45Speaker 3: maybe you'd classify and be thrown into a corner of
- 7:48Speaker 3: just being one of the bad kids. But now today
- 7:51Speaker 3: we know that we've evolved and we understand that there's
- 7:55Speaker 3: elements of what's happening to that child, what's the surrounding
- 7:58Speaker 3: of that child, what's the diet of that child, how
- 8:00Speaker 3: much exercise are they getting, how much attention are.
- 8:02Speaker 1: They getting at home? Are they even getting any attention
- 8:05Speaker 1: at home?
- 8:05Speaker 4: You know?
- 8:06Speaker 3: Are they just being given an iPad and expected to
- 8:08Speaker 3: be raised in what's happening today? So start there about
- 8:14Speaker 3: what where you're seeing today rushing to either a medication
- 8:18Speaker 3: or something, and we're not taking time sometimes with our
- 8:22Speaker 3: children to really figure out what's going on in the
- 8:24Speaker 3: first place.
- 8:26Speaker 5: Right, So we're becoming in many ways an ADHD society,
- 8:31Speaker 5: and that is probably an evolution in human existence, and
- 8:37Speaker 5: we'll see how it works. You know, evolutions sometimes works
- 8:41Speaker 5: out well and sometimes doesn't work out.
- 8:45Speaker 4: It's it's an experiment of some in some cases.
- 8:48Speaker 5: So being an ADHD person who's highly functional might actually
- 8:54Speaker 5: benefit you in certain contexts, like if you need to
- 8:57Speaker 5: be on watch and you need to notice things that
- 9:00Speaker 5: are very salient in the background, and your attention is
- 9:04Speaker 5: constantly switching. Don't forget ADHD is really not an attention deficit.
- 9:09Speaker 5: It's really an attention imbalance, meaning ADHD kids can hyper
- 9:12Speaker 5: focus on video games.
- 9:14Speaker 4: Or things that pull them in.
- 9:16Speaker 5: But if you think about like cell phones, for example,
- 9:20Speaker 5: you're constantly bombarded with new and interesting information. Certainly, sitting
- 9:24Speaker 5: kids in front of videos to placate them and keep
- 9:27Speaker 5: them satisfied, or or phones smartphones is to keep them pacified.
- 9:32Speaker 5: Then you go into a really boring classroom with a
- 9:35Speaker 5: teachers standing in front and at a board or a screen,
- 9:41Speaker 5: and the kids are checked out and then doing homework.
- 9:46Speaker 5: And then even for adults who have to multitask, or
- 9:49Speaker 5: for women who have to multitask at home and at work,
- 9:54Speaker 5: having some level of ADHD actually might be required in
- 9:58Speaker 5: our new society to be able to who shift set,
- 10:01Speaker 5: not get too stuck on one thing or the other,
- 10:02Speaker 5: and keep moving in a fast paced way. So I
- 10:05Speaker 5: think we're breeding more ADHD. Of course through technology, certainly
- 10:10Speaker 5: through our diets. Artificial colors have been examined right now
- 10:12Speaker 5: they might be pulled from the market.
- 10:14Speaker 4: Thankfully. That SA's something I've noticed in association with.
- 10:17Speaker 5: And then you ask the parents who may also have
- 10:21Speaker 5: ADHD features to parents kids who have some ADHD features, well,
- 10:25Speaker 5: they don't have the time and the patients and the
- 10:27Speaker 5: attention span to deal with it either.
- 10:28Speaker 4: They're also on a hair trigger and a short use.
- 10:31Speaker 5: So it'll be an interesting evolution to see if some
- 10:35Speaker 5: measure of increased ADHD syindematology actually ends up being necessary
- 10:39Speaker 5: and functional in our society or if it just completely
- 10:42Speaker 5: leaves as dysfunctional. But right now, people are perhaps in
- 10:45Speaker 5: some cases over using some stimulant medications which are pharmacologically
- 10:50Speaker 5: similar to cocaine and methamphetamine in order to enhance performance.
- 10:55Speaker 5: And this is a dangerous slippery slope that will we
- 10:58Speaker 5: not even be able to function that the level that
- 11:00Speaker 5: we have to without these chemicals is that where we're headed. Particularly,
- 11:05Speaker 5: you see pressure in school for this, pressure coming from
- 11:08Speaker 5: the parents, pressure coming from the teachers, pressure coming from
- 11:12Speaker 5: the therapists that we need this kid medicated for chemical
- 11:17Speaker 5: restraint for optimal performance. What are we doing?
- 11:22Speaker 1: Yes, yeah, I'm a dad.
- 11:24Speaker 3: So I have four daughters and four drastically different personalities,
- 11:31Speaker 3: and each of them have told me about aspects of
- 11:36Speaker 3: nervousness or anxiety or something, and none of it, you know,
- 11:42Speaker 3: Thank goodness at this point in my life has been extreme,
- 11:46Speaker 3: but it's definitely an impacted speech. Where one of my children,
- 11:50Speaker 3: one of my daughters, wasn't able to communicate with their
- 11:53Speaker 3: teachers because of nervousness, would shut down, and they called
- 11:56Speaker 3: it selective mutism, and shout out to the school. They
- 12:00Speaker 3: did an amazing job helping to condition her and pull
- 12:02Speaker 3: her out of that. We got her into plays and
- 12:05Speaker 3: now she's addicted to plays and she's a chatterbox and
- 12:08Speaker 3: she's opening up and she's do do do do do well?
- 12:11Speaker 3: That was an element of anxiety that we're noticing and
- 12:16Speaker 3: paying much more attention today, which is the good side
- 12:19Speaker 3: of evolution of medicine than what you and I grew
- 12:22Speaker 3: up in when I, when we were younger, when I
- 12:24Speaker 3: was younger, I know, in the seventies, it was just
- 12:27Speaker 3: you're a bad kid, and you know, or you're dumb
- 12:30Speaker 3: because you haven't paid enough attention to the material because
- 12:33Speaker 3: you really couldn't because you couldn't, you know, even sit still.
- 12:37Speaker 3: And now you know, at least we're giving that at
- 12:39Speaker 3: least worth flagging kids with this these issues. But to
- 12:43Speaker 3: your point, when do people like you and I who
- 12:47Speaker 3: experienced a different way of life and culture. We're going
- 12:50Speaker 3: to all die out and then then the generations after us.
- 12:54Speaker 3: Are you saying that we're going to evolve into just
- 12:57Speaker 3: becoming an ADHD, you know, as we'll just become part
- 13:01Speaker 3: of humanity in our evolution.
- 13:05Speaker 4: Well, we'll see where it goes.
- 13:06Speaker 5: I mean, there's some benefits of ADHD in terms of
- 13:09Speaker 5: the creativity side. Many kids and adults who have ADHD
- 13:13Speaker 5: are the most highly creative and funny and spontaneous people.
- 13:17Speaker 5: And if they're on the wrong treatment, while they may
- 13:20Speaker 5: be more focused and behaved, they can feel like they've
- 13:23Speaker 5: lost their personality, they lost their juice, they lost their creativity.
- 13:26Speaker 5: So you could think of it, like I said, an
- 13:29Speaker 5: inverted U shaped curve where you know, if you're completely
- 13:33Speaker 5: you know, highly symptomatic, you're completely dysfunctional. And then as
- 13:36Speaker 5: you sort of turn the dial let's say, up on
- 13:39Speaker 5: the treatment and you get more and more focused. In
- 13:41Speaker 5: if you overturn it, you can get more depressed, you
- 13:43Speaker 5: can get more hyper focused, you can get more irritable
- 13:45Speaker 5: and agitated and even psychotics. So you know, there's a
- 13:49Speaker 5: balance here between intervening not intervening intervening with the most
- 13:54Speaker 5: favorable treatments that address the whole person and not just
- 13:58Speaker 5: having someone medicated and strained. So it's a balance, like
- 14:02Speaker 5: you know, most.
- 14:02Speaker 4: Things in life.
- 14:03Speaker 5: You know, it's not all good or all bad. It's
- 14:05Speaker 5: not like anti meds or pro meds. It's not like
- 14:07Speaker 5: we should diagnose or we shouldn't diagnose. We wanted people
- 14:10Speaker 5: to be doing as well as they can do while
- 14:13Speaker 5: still appreciating the way they were made and the talents
- 14:18Speaker 5: and the abilities that they have that were you know,
- 14:21Speaker 5: naturally innate within them and developing them. So getting kids
- 14:25Speaker 5: into something that they really enjoyed, maybe it's taekwondo, maybe
- 14:29Speaker 5: it's art, maybe it's music, could help them develop their
- 14:33Speaker 5: brains into a more focused way for other things that
- 14:38Speaker 5: they may not have ever been more interested in. Because
- 14:40Speaker 5: if you can get out of that window, that critical
- 14:42Speaker 5: period role, the synaptic pruning happens, you know, the pruning
- 14:45Speaker 5: at the bushes of the tree, so you can get
- 14:47Speaker 5: those nice tracks and developmental nourishment to kind of you know,
- 14:54Speaker 5: nourish the brain into its its more final form. It's
- 14:58Speaker 5: it's solidified form that might that might be able to
- 15:03Speaker 5: be accomplished just by tapping into some of the innate
- 15:06Speaker 5: strengths of every unique child. And that's going to involve
- 15:10Speaker 5: a paradigm shift in our educational system. You know, not
- 15:13Speaker 5: every kid can just participate in frontal learning with one
- 15:16Speaker 5: teacher and thirty kids or forty kids in a room.
- 15:18Speaker 5: They meet some smaller class sizes, different types of learning,
- 15:21Speaker 5: like gardeners, multiple intelligences. We need all these types of
- 15:25Speaker 5: people in our society, not just those who are masters
- 15:29Speaker 5: of reading, writing, a math. They should be competent, but
- 15:31Speaker 5: they have other things to offer us that will move
- 15:34Speaker 5: society forward, and we don't want to squash that or
- 15:36Speaker 5: just favor one type of intelligence over another.
- 15:40Speaker 1: Absolutely.
- 15:41Speaker 3: So, the pandemic was a horrible time in our modern history,
- 15:47Speaker 3: and it was so recent that everyone that's in business
- 15:52Speaker 3: and in the business of healthcare and in pharmacy remembers
- 15:56Speaker 3: exactly how it impacted our nation. That also threw us
- 16:00Speaker 3: into a laboratory like environment where we had our kids
- 16:04Speaker 3: at home. Some of them weren't going to school, so
- 16:07Speaker 3: they were there, and it did give a lot of
- 16:11Speaker 3: feedback in time for us to dial into the way
- 16:14Speaker 3: that our children were feeling. And I asked to this
- 16:17Speaker 3: day all four of my daughters, two of them were
- 16:21Speaker 3: still in grade school at that time. What that experience
- 16:25Speaker 3: was like. And this paper that we referenced as we
- 16:28Speaker 3: got started says that the pandemic helped us to really
- 16:33Speaker 3: hyper focus into some of our children's issues because we
- 16:37Speaker 3: had much more time with them, and there was good
- 16:41Speaker 3: that came out of it because there was also bonding
- 16:44Speaker 3: between parents and children in ways that there wasn't and
- 16:47Speaker 3: it also poured back into the pediatrics and psychiatry side.
- 16:52Speaker 3: We're really dialing into the data that's coming out to
- 16:54Speaker 3: a lot of these studies and now we're post pandemic
- 16:58Speaker 3: and we're moving forward. This is a new year, so
- 17:02Speaker 3: this is a special time for pharmacists who are out
- 17:04Speaker 3: there who are really interested in the psychology side of
- 17:10Speaker 3: the pharmacological world and working with psychiatrists and working with specialists.
- 17:16Speaker 3: There are so many out there that a rise out
- 17:18Speaker 3: of our health systems, but they also are looking to
- 17:20Speaker 3: do more private practice consulting as well.
- 17:23Speaker 1: And shout out to Jenna Quinn who's doing exactly that.
- 17:26Speaker 3: What is some of the go forward from the data
- 17:30Speaker 3: that you have, Do you think we should start with
- 17:34Speaker 3: children and adults because you're helping and referencing adult studies too.
- 17:40Speaker 3: Where do we go now that we have so much
- 17:41Speaker 3: more data, we have more information, we have better technologies,
- 17:45Speaker 3: definitely better medications.
- 17:47Speaker 1: What's next?
- 17:48Speaker 3: Should we start moving to pharmacogenomics first or start to
- 17:52Speaker 3: test and start to really start to build a hyper
- 17:56Speaker 3: focused way of treatment quicker and faster than and sometimes
- 18:01Speaker 3: it's taken in my case back in the seventies, didn't
- 18:03Speaker 3: even get time to diagnose it.
- 18:06Speaker 1: Right.
- 18:06Speaker 3: Well, now look look how far we've come. So what,
- 18:09Speaker 3: in your opinion, what's next?
- 18:11Speaker 5: So I think what's next is looking at preventative strategies
- 18:14Speaker 5: because right now I think people are running for the
- 18:17Speaker 5: medications for the quick fix, and they're not necessarily considering
- 18:22Speaker 5: the long term consequences of that, both psychologically and chemically.
- 18:27Speaker 5: So if we have these medications, I prefer the non
- 18:31Speaker 5: stimulants rather than things like I said that are derivatives
- 18:34Speaker 5: of cocaine and methamphetamine. But I think that we should
- 18:38Speaker 5: evolve our educational systems, our parenting coaching, and our professional
- 18:45Speaker 5: interactions with kids to try to explore and fully exhaust
- 18:50Speaker 5: all the non pharmacologic agents and interventions and even natural things.
- 18:56Speaker 5: Lifestyle things En Richmond, things before we jump to medication.
- 19:00Speaker 5: And so it's wonderful when that comes from a pharmacist
- 19:02Speaker 5: because people are so taken aback when it comes from
- 19:05Speaker 5: a physician like myself, like, wow, a doctor would recommend
- 19:08Speaker 5: something other than medications. Yes, And it resonates so powerfully
- 19:12Speaker 5: because it came.
- 19:13Speaker 4: From a medical professional. It was a prescription for health.
- 19:16Speaker 4: It wasn't just a prescription for meds.
- 19:19Speaker 2: Right.
- 19:20Speaker 3: That's awesome, that's great, and that's where we're moving. That's
- 19:23Speaker 3: where we see pharmacy moving. There's a lot of there's
- 19:26Speaker 3: a lot of worry in our profession right now. We
- 19:28Speaker 3: have a collapse of the fast food pharmacy market where thousands,
- 19:36Speaker 3: over seven thousand pharmacies have closed throughout throughout the United
- 19:40Speaker 3: States within the last four years. There are we're now
- 19:44Speaker 3: seeing cracks in the realm of education. Of the one
- 19:47Speaker 3: hundred and forty two pharmacy schools, one has closed in
- 19:50Speaker 3: West Virginia. It's a time to see that the evolution
- 19:56Speaker 3: of pharmacy is I mean, it's changing. It's in the
- 20:00Speaker 3: all of the pharmacists is changing. If there were more
- 20:02Speaker 3: pharmacists that were being paid to dial into a specific theme,
- 20:07Speaker 3: let's say, in mental health for goodness sakes, because we
- 20:10Speaker 3: need that more than ever. Really, I know it, you
- 20:13Speaker 3: know it. So now we have pharmacists who could concentrate
- 20:16Speaker 3: on taking groups of adults and groups of athletes, and
- 20:19Speaker 3: groups of women, groups of men, groups of children, groups
- 20:22Speaker 3: of you know, so many subsets of geriatrics and people
- 20:26Speaker 3: over sixty five. Each of those demographic sectors of human
- 20:32Speaker 3: beings are different, and could you could really, as a pharmacist,
- 20:36Speaker 3: dial into each of them.
- 20:38Speaker 1: And that's why I'm.
- 20:39Speaker 3: A glass half full kind of attitude guide because I
- 20:41Speaker 3: see a future of pharmacy going to be much different
- 20:44Speaker 3: than what I grew up in in seventies, eighties, nineties,
- 20:48Speaker 3: and now it's an opportunity. So people like you get
- 20:52Speaker 3: me excited because you're bringing a lot of that day
- 20:54Speaker 3: to the table. So this is why we've appreciated this
- 20:57Speaker 3: conversation with you, Richard.
- 21:00Speaker 5: It's almost like going back to the past because my
- 21:01Speaker 5: father would tell me stories where he had a very
- 21:04Speaker 5: close relationship, you know, with his whatever you want to
- 21:07Speaker 5: call it, Gangal's patients, maybe his clients, his customers are
- 21:10Speaker 5: every want to call it, and you know, he would
- 21:12Speaker 5: deliver things to their homes. He would see them in
- 21:14Speaker 5: their homes back in the old days. He would compound medication.
- 21:19Speaker 5: He would There was even like herbal remedies back then
- 21:22Speaker 5: that people were taking or supplements or things, and they
- 21:25Speaker 5: were quite knowledgeable. There was a class called pharmacogncy, which
- 21:29Speaker 5: was not you know, necessarily medications that were you know,
- 21:32Speaker 5: FGA approved typical medications, but they were interventions that pharmacists
- 21:36Speaker 5: would do back at the old apothecary, that's what it
- 21:38Speaker 5: was called. And they had more of a holistic bent
- 21:41Speaker 5: back in those days, probably because there were fewer medication options,
- 21:44Speaker 5: but people were still plugged in then to things that
- 21:47Speaker 5: weren't necessarily medications per se, but were still interventions that
- 21:52Speaker 5: pharmacists were quite schooled.
- 21:55Speaker 3: And then, yeah, I think of life expectancy over the
- 21:59Speaker 3: LA last say twenty five years, right, and I wonder.
- 22:06Speaker 1: Evolution of medication.
- 22:08Speaker 3: Obviously vaccines goodness gracious and saving millions and billions of
- 22:12Speaker 3: people's lives based on things like pollio for example. So
- 22:16Speaker 3: modern medicine is just freaking amazing. It's I read about
- 22:20Speaker 3: what you're doing, what you are doing specifically, and what
- 22:24Speaker 3: our pharmacists are doing, and it blows my mind. However,
- 22:30Speaker 3: I almost think that there's this strange balance between coming
- 22:36Speaker 3: from the dark ages and not having any medication dial
- 22:39Speaker 3: in abilities to save people's lives. But then all of
- 22:42Speaker 3: a sudden, when does the needle go the opposite way
- 22:46Speaker 3: where you're like, wait a second now, So we have
- 22:49Speaker 3: to look at life expectancy. Life expectancy for a twenty
- 22:51Speaker 3: five year old in the United States is fifty two
- 22:54Speaker 3: point four years for men, fifty six point nine years
- 22:59Speaker 3: for women. However, life expectancy in the US has to
- 23:01Speaker 3: be in declining, so they're saying that added on to
- 23:04Speaker 3: twenty five years. So I mean, that's that sounds pretty
- 23:07Speaker 3: good to me. I mean, you're getting into your nineties,
- 23:09Speaker 3: and I remember, you know, my both of my grandmothers.
- 23:13Speaker 3: My one grandmother's ninety eight, she's still living, and my
- 23:17Speaker 3: other grandma died at ninety five. So I think my
- 23:21Speaker 3: my personal chances from a genetic perspective is good. But
- 23:26Speaker 3: talk to us about life expectancy and longevity, but better yet,
- 23:32Speaker 3: living good lives, not you know, not being in a
- 23:35Speaker 3: wheelchair or being you know, because you didn't take care
- 23:38Speaker 3: of yourself, or because you allowed diabetes to run off.
- 23:41Speaker 3: But talk to us about that quality of life and
- 23:44Speaker 3: life expectancy and journey.
- 23:47Speaker 5: Yeah, so we have to think about some things which
- 23:49Speaker 5: are very obvious that minimize life expectancy, and that's violence
- 23:55Speaker 5: and fentanyl overdoses and things that are really entirely inventible,
- 24:00Speaker 5: societal issues that take young people way too young who
- 24:04Speaker 5: are otherwise fairly healthy.
- 24:09Speaker 4: Nutrition.
- 24:10Speaker 5: We're not doing well on the nutritional front compared to
- 24:13Speaker 5: some other let's say, less quote unquote advanced countries that
- 24:17Speaker 5: don't have the most modern medicines. We're not doing so
- 24:19Speaker 5: well in that sleep, exercise, stress management, even just living
- 24:27Speaker 5: a life of meaning and purpose. Perhaps spirituality can have
- 24:31Speaker 5: longevity impact. So end of life care. So let's say
- 24:38Speaker 5: a person is living tiny, you know, what is their
- 24:42Speaker 5: quality of life? Let's say from eighty to ninety? You know,
- 24:45Speaker 5: are there on a ventilator for many years? Are they
- 24:47Speaker 5: having ulcers and bed sores and we're prolonging their life
- 24:52Speaker 5: as much as we can to get a higher number
- 24:54Speaker 5: in more years? Is their quality of life at that point?
- 24:59Speaker 5: So these are all facts is that go into that
- 25:00Speaker 5: overall number of life expectancy. Of course, COVID took a
- 25:04Speaker 5: hit in that, but we were recovering from that, and
- 25:07Speaker 5: you know, are we playing around with viruses, you know,
- 25:10Speaker 5: in terms of gain function and making superviruses that we
- 25:12Speaker 5: can't keep up with. These are things that we can do,
- 25:17Speaker 5: not to beat death, it's inevitable, but to live better lives.
- 25:23Speaker 5: And we need to get our priorities straight in terms
- 25:26Speaker 5: of what's important and how far science should go and
- 25:30Speaker 5: where science should not go. And I think it has
- 25:33Speaker 5: mental health implications because while it's these these smartphones and
- 25:37Speaker 5: technology and AI has great potential, it also is creating
- 25:42Speaker 5: a lot of stress and a lot of disruption in
- 25:45Speaker 5: our circadian rhythms and our hormones and in our life expectancy.
- 25:50Speaker 5: It's perhaps you know, making certain things easier, but we're
- 25:52Speaker 5: not adapting as humans fast enough as the technology evolves.
- 25:58Speaker 5: And these are just things we have to consider as
- 25:59Speaker 5: we bring in new technology, and as we regulator, we
- 26:02Speaker 5: try to regulate it, which we're not really regulator. Oh
- 26:06Speaker 5: it's new, it's new, it's new, Keep going, keep going going, Yeah,
- 26:08Speaker 5: but at what costs? So it's like you're spinning in
- 26:11Speaker 5: the winds. You know, you have a lot of these
- 26:12Speaker 5: systemic factors going against you know, some really excellent medications
- 26:16Speaker 5: that are more effective, better tolerability.
- 26:18Speaker 4: But then what are we doing overall for the picture?
- 26:20Speaker 5: And as the doctor patient encounters become shorter and shorter
- 26:23Speaker 5: and shorter, you know, with fan managed care pressures, that
- 26:27Speaker 5: opens up a portal for perhaps pharmacists and other specialists
- 26:31Speaker 5: who may feel they have additional time to spend with
- 26:34Speaker 5: the patient. Because used to be when someone called my
- 26:37Speaker 5: father and say, what do you think about this medication?
- 26:39Speaker 5: Because I ask your doctor, ask your doctor. I might
- 26:41Speaker 5: your doctor ask your doctor, and then the doctor would
- 26:43Speaker 5: be responsible.
- 26:44Speaker 4: I'm certainly responsive.
- 26:45Speaker 5: People text me all day and all night, and I
- 26:46Speaker 5: give them advice all day long. So I'm responsive when
- 26:49Speaker 5: the pharmacists dispensing medical advice and not consulting with the position.
- 26:53Speaker 5: We want to work together. We don't want one undermining
- 26:56Speaker 5: the other. So if someone says, give us a piece
- 26:58Speaker 5: of medical advice of context as a pharmacist and say,
- 27:02Speaker 5: but they don't know your case, they don't know your situation,
- 27:04Speaker 5: I'm not prescribing it for that. I'm not prescribing it
- 27:07Speaker 5: for another reason that's not listed in the book.
- 27:09Speaker 4: Oh I didn't know.
- 27:10Speaker 5: That, So now you have to call the pharmast and
- 27:12Speaker 5: say why did you tell my patient this? We want
- 27:14Speaker 5: to work together because we all want the benefit of
- 27:16Speaker 5: the patient.
- 27:17Speaker 3: Yes, that's where the electronic health record outreach and interconnections
- 27:22Speaker 3: are coming in, where pharmacists are now able to communicate
- 27:26Speaker 3: back to a physician in notes, in saying hey, here's
- 27:30Speaker 3: a suggestion, or here's something that's going to happen from
- 27:33Speaker 3: this dosing, or hey could I run a PGX test
- 27:36Speaker 3: because we keep you know, missing the right medicaid whatever
- 27:40Speaker 3: it is. It's that opportunity to communicate, document, communicate, adjust,
- 27:46Speaker 3: and is where that pharmacist can become that right hand
- 27:49Speaker 3: of the of the quarterback of the case for the
- 27:53Speaker 3: patient and mental health specifically because of you know, making
- 27:59Speaker 3: slight adjustments in suggestions of what they could do to
- 28:03Speaker 3: help help an individual. So the personalization of medicine is
- 28:08Speaker 3: exciting because I do see things changing, and certainly I'm impatient.
- 28:13Speaker 3: I'd like to see it happen faster, but it is.
- 28:15Speaker 3: I do see it changing, and I see it getting
- 28:17Speaker 3: better where we are dialing into individual people's needs and
- 28:21Speaker 3: we're seeing that pharmacists are having an opportunity to participate
- 28:24Speaker 3: in that. So this has been a wonderful conversation. Richard,
- 28:28Speaker 3: Is there any reference of data reporting or anything else
- 28:32Speaker 3: that you can give a shout out to of where
- 28:35Speaker 3: pharmacists that are interested in ADHD medications helping their patients
- 28:41Speaker 3: and doing maybe more for their patients than what they're doing.
- 28:44Speaker 5: Well, just as a selfish plug. But I don't think
- 28:46Speaker 5: it's a selfish plug. I think it really is a
- 28:48Speaker 5: good article. So it's extended release the loxazine compared with
- 28:51Speaker 5: atomoxetine for attention deficit hyperactivity disorder. Lead author is Maxwell
- 28:57Speaker 5: Zachary Price. I'm the second author, Richard Lewis Price. It
- 29:01Speaker 5: was probablished July twenty twenty three in CNS Drugs. What
- 29:06Speaker 5: we do there is we look at the entire landscape.
- 29:08Speaker 5: But like if you have a patient come in and
- 29:10Speaker 5: they're like predominantly add they they're just inattentive just for.
- 29:14Speaker 4: Like a few hours a day for some high.
- 29:16Speaker 5: Needs of a school or for work or whatever, and
- 29:19Speaker 5: they have no comorbidities whatsoever, So perhaps the stimulant is appropriate.
- 29:23Speaker 5: I would use methylbenada before I would use amphetamine emfetami.
- 29:26Speaker 5: It's more powerful, more side effects, okay, but then more
- 29:29Speaker 5: often than not, you have what's called comorbidities. You have
- 29:33Speaker 5: ADHD that lasts the entire day. It affects your self esteem,
- 29:36Speaker 5: it affects your mood, it affects anxiety, it affects your
- 29:39Speaker 5: executive functioning. You need something that's going to cover you morning,
- 29:42Speaker 5: noon and night. So if it's predominantly hyperactive and impulsive,
- 29:45Speaker 5: so the alpha two agonist, the glofacine extend to release
- 29:48Speaker 5: the quantityine extended release. There's now a liquid quantity now
- 29:51Speaker 5: called Onnita, very helpful for people who need to tyrate
- 29:55Speaker 5: doses and for kids, perhaps that's the best choice.
- 29:59Speaker 4: But then you have.
- 29:59Speaker 5: Some new You have a looxazine eer, you have kelbre right.
- 30:03Speaker 5: So everybody thinks Calbery is the same as stratera, it's not.
- 30:05Speaker 5: That's what our study looked at. So with stratera, it's
- 30:08Speaker 5: more rapidly act, more rapidly acting than straterra. It's more
- 30:11Speaker 5: effective than straterra, it's better tolerted than straterra. It doesn't
- 30:16Speaker 5: have the same metabolism estratera in terms of adjusting doses.
- 30:20Speaker 5: It's just an entirely different mechanism. You know, it's not
- 30:23Speaker 5: just an RP efer reuptake inhibitor. It's a mild one
- 30:26Speaker 5: unlike STRATERA. It's also works not as an ssri. Everybody thinks,
- 30:30Speaker 5: isn't that it's not an ssri and it's not a
- 30:32Speaker 5: dopam reuptake inhibitor. It's five HT two. You b five
- 30:36Speaker 5: HT seven antagonists and a partial agonist at five HT
- 30:41Speaker 5: two C. Now that may sound like gibberish, but the
- 30:43Speaker 5: net result is you are increasing prefrontal cortex dopamine, noorpinephrin,
- 30:49Speaker 5: and serotonin without being a reuptake inhibitor of serotonin or dopamine.
- 30:54Speaker 4: That's an entirely different mechanism.
- 30:57Speaker 5: So where does calpre final role For those who need
- 31:00Speaker 5: focus but they don't want to stimulant stimulants have side
- 31:03Speaker 5: effects appetite suppression, ticks, anxiety, wearof insomnia. These are very
- 31:09Speaker 5: common comorbidities that patients may have. Anyway, we don't want
- 31:12Speaker 5: to exacerbate that. Well, stimulants are the gold standard. Well
- 31:15Speaker 5: maybe they're not the gold standard for every patient. Maybe
- 31:18Speaker 5: as we involve new treatments, we have to revise our algorithm.
- 31:22Speaker 5: This is what the clinical experience will teach you that
- 31:26Speaker 5: you won't get in the books, but by publishing this,
- 31:28Speaker 5: it gets in the books and now people who like
- 31:31Speaker 5: to reference data can put this into their clinical experience.
- 31:34Speaker 5: So where calbry distingus itself, people have comorbid anxiety, comorbid depression.
- 31:38Speaker 5: Calbrey was an antidepressant in Europe for thirty years as
- 31:42Speaker 5: an immediate release blocosine IR brought to this country made
- 31:47Speaker 5: into an extended release called Calbrey, not bio equivalent. So
- 31:51Speaker 5: it helps depression, helps anxiety, helps the full spectrum of ADHD,
- 31:54Speaker 5: the inattentive, the hyperactive, the impulsive, rapidly acting ftaproof for kids,
- 32:00Speaker 5: update Proof for adults helps kids sleep at night. Help
- 32:03Speaker 5: it's given for adults in the morning helps them with wakefulness.
- 32:06Speaker 5: So these are things that this article explores in a
- 32:09Speaker 5: controlled study type of way that I think is landmark
- 32:13Speaker 5: because people don't know what Calbury is and I'm not
- 32:15Speaker 5: promoting Calbrey. I'm just promoting doing right by your patient
- 32:19Speaker 5: and not just going to treatment guidelines and algorithms one
- 32:22Speaker 5: size fits all approach. So I invite people to learn
- 32:24Speaker 5: more about where Calbury fits in the algorithm. The new
- 32:28Speaker 5: algorithm I would say of treating your patient. And that's
- 32:31Speaker 5: one resource, but I also invite people to check out
- 32:34Speaker 5: the Supern's website because we're going to be doing webinars
- 32:37Speaker 5: throughout the country through different time zones where I believe
- 32:41Speaker 5: clinicians of all kinds can log in and learn more
- 32:44Speaker 5: about ADHD, disease date and also Calbrey and have hopefully
- 32:49Speaker 5: an interactive, rich discussion where they can write in questions
- 32:52Speaker 5: and I can get to meet the people who are
- 32:54Speaker 5: listening to this podcast, because this needs to go far,
- 32:56Speaker 5: and why not just to clinicians, to parents want to
- 32:59Speaker 5: learn more, and adolescents and adults want to learn more
- 33:04Speaker 5: about what ADHD is, what it isn't and how to
- 33:08Speaker 5: get a guided toward the best treatment that meets their
- 33:12Speaker 5: needs and not just looking at numbers and effects size
- 33:16Speaker 5: and algorithms. ADHD you could say has comer biddies, or
- 33:20Speaker 5: you could say that the comorbiddies are so common that
- 33:23Speaker 5: these are part and parcel of the ADHD itself.
- 33:29Speaker 3: Doctor Price. We're going to have links inside the show
- 33:32Speaker 3: notes of this podcast episode. If you're driving, if you're jogging,
- 33:36Speaker 3: if you are just listening right now, there's no problem whatsoever.
- 33:41Speaker 3: Take your time, get back to somewhere safe. If you
- 33:43Speaker 3: are where you can go to a website. Supernas Publications
- 33:50Speaker 3: is where this is at, and you start off at
- 33:52Speaker 3: the homepage which is Supernus or sup n Publication supernus
- 34:01Speaker 3: dot com. We will have once again links in our
- 34:04Speaker 3: show notes to take you to this website, these references
- 34:08Speaker 3: and the public publication search directories that they have, and
- 34:12Speaker 3: then also we're going to put a link into the
- 34:14Speaker 3: show note that you said, Richard and your article that
- 34:18Speaker 3: you've published, because we want our pharmacists to have access
- 34:21Speaker 3: to that too. Hope you'll come back. We'd like to
- 34:24Speaker 3: have some pharmacists on with you that do specialize in
- 34:28Speaker 3: mental health and dialing down into even ADHD and have
- 34:31Speaker 3: an additional discussion. We'd like to talk to you again
- 34:36Speaker 3: in the Geriatrics forum and really talk about the population
- 34:40Speaker 3: that's going to be one of our most important demographics
- 34:43Speaker 3: and the attention that pharmacist and physicians are on for
- 34:46Speaker 3: the next twenty five to thirty years.
- 34:48Speaker 1: And then of course I'll be old.
- 34:50Speaker 3: By then too, so please I want to be better
- 34:53Speaker 3: taken care of in those days.
- 34:54Speaker 1: But Richard, this has been wonderful. Thanks for doing this
- 34:58Speaker 1: and being our guest today.
- 34:59Speaker 4: Thank you so much. You will